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In chronic viral hepatitis, autoimmune hepatitis, and some chronic cholestatic
liver diseases, T-lymphocytes serve as effector cells of the immunostimulatory
processes. Cellular interactions of immune cells with extracellular matrix
(ECM) components are regulated primarily via the f1 subfamily of integrin
receptors. The target epitope of several such integrin receptors is the Arg-Gly-
Asp (RGD) sequence, a cell adhesion motif shared by several matrix-associat-
ed adhesive glycoproteins. We review the use of synthetic nonpeptidic ana-
logues ofRGD and ofsoluble receptor oftumor necrosis factor (TNF)-a in the
prevention ofimmune-mediated, concanavalin A-induced liver damage in mice
and of RGD analogues in inhibiting the development of liver cirrhosis in rats.
The concanavalin A-induced elevation of serum transaminases and TNF-a, and
the infiltration ofliver tissue by inflammatory cells, were inhibited by pretreat-
ment of the mice with the synthetic RGD mimetics and soluble TNF receptor.
In rats, the progression of thioacetamide-induced liver cirrhosis was markedly
inhibited by the coadministration of the RGD mimetic SF-6,5. The compounds
described here may be examined therapeutically for pathological conditions in
the liver, manifested as necroinflammation, cholestasis and fibrosis.
In several liver diseases, including chronic viral hepatitis, autoimmune chronic active
hepatitis, and cholestatic liver diseases such as primary biliary cirrhosis and primary scle-
rosing cholangitis, T-lymphocytes serve as effector cells of the immunostimulatory
processes. The inflammatory cell infiltrate is thought to contribute to liver injury either as
a primary event, as in autoimmune hepatitis and primary biliary cirrhosis, or as a sec-
ondary response to another process such as chronic viral infection. In response to acute
injury, T-cell activation results in production of cytokines such as tumor necrosis factor
(TINF)-ad and IL (interleukin)-2, which maintain and augment the level ofthe inflamma-
tory process and may induce acute toxicity. The accumulation ofmononuclear cells at the
site of injury depends in part on their ability to penetrate the sinusoidal endothelial cells
and their adhesion to the extracellular matrix in the space of Disse. Both these processes
are mediated by integrins, a family of cell surface adhesion receptors. Several matrix and
plasma-associated glycoproteins such as fibronectin (FN) are recognized by integrins via
the Arg-Gly-Asp (RGD) cell adhesion epitope.
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The E. Wolfson Medical Center, Holon 58100, Israel. Tel.: 972-3-5028499; Fax: 972-3-5044634.
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In this paper, we will review the use of synthetic analogues of the extracellular
matrix-associated epitope RGD and soluble receptor ofTNF in the prevention ofimmune-
mediated hepatitis, and of RGD mimetics in inhibiting hepatic fibrosis in experimental
models of acute and chronic liver injury.
THE EXTRACELLULAR MATRIX-ASSOCIATED EPITOPE
Arg-Gly-Asp (RGD) IN CELL ADHESION
Cellular interactions ofimmune cells with ECM components are regulated primarily
by a family of transmembrane heterodimeric cell surface adhesion receptors of the inte-
grin family [1-4]. Each integrin is composed of a noncovalently associated a and 3 sub-
unit. The P1 subfamily of integrins, also referred to as VLA (very late activation) recep-
tors, are specific for various glycoprotein ligands of the ECM, such as FN, laminin, col-
lagens, and vitronectin [4, 5]. Although the characterization and localization of integrin
recognition sites on ECM glycoproteins has not been completely elucidated, the involve-
ment of the Arg-Gly-Asp- (RGD) epitope in cell adhesion processes has been indicated
[2, 6]. The RGD cell adhesion motif is also present in several matrix and plasma-associ-
ated glycoproteins such as FN, and is recognized by several integrins, including aIIcb133 on
platelets, a3P1 (VLA-3), a5I1 (VLA-5), and most of the av-containing integrins [3].
Upon cell activation, the RGD-containing sequence is recognized by several integrin
receptors that mediate RGD-dependent matrix adhesion of cells. Interactions between
immune cells and FN determine the subsequent activation and proliferation of the cells,
and the secretion ofcytokines such as TNFa, TGFB and fibroblast growth factor [8, 9].
The use of RGD-containing peptides to prevent T cell-mediated inflammatory reac-
tions has been suggested [7]. However, since these short RGD-containing peptides are
highly susceptible to proteolysis, their preventive effect required pretreatment of the
migrating cells with high concentrations of the RGD peptides, rather than in situ admin-
istration of the peptides [7]. Therefore, the clinical usage of such compounds to prevent
damage due to T-cell-mediated inflammatory reactions in vivo is not practical.
NONPEPTIDIC MIMETICS OF RGD
We recently described the design and synthesis of novel nonpeptidic mimetics of
RGD that contain guanidinium and carboxylate groups separated by an atom spacer, thus
mimicking the functional groups ofRGD [8]. Compound SF-6,5, is a nonpeptidic mimet-
ic ofRGD, which has an 11 atom spacer between the guanidinium and carboxylic groups
that mimics the atomic spacing between the two groups in the RGD peptide. Compound
NS-11 is a conformationally constrained RGD mimetic molecule, that was obtained by
substituting a piperidine unit into a spacing chain [9]. The ring substitution in compound
NS-11 restricts the conformational freedom of the carboxylate and guanidinium moieties
in a constant spatial arrangement (Figure 1). These mimetics specifically inhibited (i)
RGD-dependent platelet aggregation, and (ii) binding of T-lymphocytes and tumor cells
to immobilized fibronectin and vitronectin. Also, we demonstrated that an RGD mimetic
specifically inhibits actively induced, delayed-type hypersensitivity reactions and tumor
cell colonization in mice [9, 10], suggesting the involvement of RGD recognition in reg-
ulation of immune responses and migration of cells involved in pathological responses.
The RGE (Arg-Gly-Glu acid) mimetic, SF-6,6, which has a 12-atom spacing chain
between the two ionic functional groups (Figure 1), and therefore lacks integrin specifici-
ty, was synthesized to be used as control.
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Figure 1. Schematic presentation of the RGD-peptide, and the RGD and RGE mimetics.
Adapted from Ref. [15].
EFFECTS OF THE RGD MIMETICS ON T-CELL ADHESION TO
FIBRONECTIN AND LAMININ
To compare the ability ofthe mimetics to inhibit the adhesion ofP1 integrin-express-
ing cells, the binding ofmurine T-cells to immobilized fibronectin and laminin in the pres-
ence of the mimetics and RGD and RGE-containing peptides (100 ,ug/ml) was studied.
Compounds SF-6,5, NS-11 and the RGD-containing peptide, GRGDSP, inhibited T-cell
adhesion to fibronectin (Table 1; Ref. [15]). Compound SF-6,6 did not inhibit T-cells
adhesion, which is consistent with the inability ofRGE-peptides to interfere with integrin
recognition of RGD-containing ECM ligands [5]. The inhibitory effect of the RGD
mimetics was notdue to atoxic effect since: (i) theT-cells completely recovered their abil-
ity to adhere to fibronectin when the compounds were removed by washing and the cells
maintained in culture for 24 hr, (ii) neither NS-11 nor SF-6,5 inhibited the binding of T-
lymphocytes to laminin (Table 1; Ref 15), and (iii) none of the mimetics inhibited T-cell
proliferation in response to concanavalin A (Table 2; Ref. [15]). These findings indicate
that the inhibitory actions of SF-6,5 and NS-11 on T-cells adhesion are specific and
restricted to immune cell-ECM interactions.
IMMUNE-MEDIATED, CONCANAVALIN (CON) A - INDUCED HEPATITIS
Recently, an animal model ofimmune-mediated, T-cell-dependent, liver damage was
introduced in mice. In this experimental model, liver damage is recognizable by signifi-
cant elevation of serum aminotransferases 6-8 hr after the intravenous administration of
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the lectin concanavalin (Con A) [11]. The induction of Con A hepatitis depends on the
interaction between CD4+ T-helper cells and macrophages [11], and as recently reported,
on the production of cytokines, notably TNF-cx, and IFN-y [12, 13]. When examined by
electron microscopy, livers from ConA-treated mice demonstrated severe cellular damage
as early as 4-6 hr after Con A administration [11], whereas histologic changes could be
demonstrated by light microscopy only 24 hours after the inoculation of Con A [13]. A
recent study have suggested that Con A-induced apoptosis of liver cells is dominantly
mediated by a perforin-dependent pathway through ICAM-l/ILFA-1 interaction and not
through the Fas ligand pathway [14]. This mouse model of acute liver damage, might be
useful for the investigation ofthe pathogenesis and the efficacy ofexperimental treatment
modalities in chronic hepatic inflammation and in some cholestatic liver diseases as well,
since similar processes take place during an immune response to chronic liver insult.
Table 1. Effects ofRGD-peptide and mimetics on T-cells adhesion to fibronectin and laminin.
Inhibitory compound Percent adhesion ofactivated T-cells to:
(100 l g/ml) fibronectin laminin
None 34±4 38±5
GRGDSP 17 ± 2* (50)a 36 ± 4
GRGESP 33 ±4 40±4
NS-11 13±3* (61) 36±5
SF-6,5 19 ± 2* (56) 37 ± 6
SF-6,6 34 ± 2 34 ± 6
Adhesion of activated murine T-cells to ECM-glycoproteins in the presence of various inhibitors
(100 ,ug/ml).-
a Percent inhibition is indicated. *p < .01: experimental vs. control group. Unless indicated, no sig-
nificant inhibition was observed. n = 5. Adapted from Ref. [15].
Table 2. Effects of the nonpeptidic mimetics ofRGD and RGE on T-cell proliferation.
Addition T-cell proliferative response
(100 ig/ml) (CPM x 103 + SD)
Control Con A
None 5 ± 1 172 ± 10
SF-6,6 3±2 169±13
NS-11 2±1 180±17
SF-6,5 4±2 180±17
GRGDSP 4± 1 170 ± 11
T-cells were purified from spleens ofBALB/c mice, left untreated (control), or activated with Con
A, in the presence or absence of the nonpeptidic mimetics ofRGD and RGE. One ofthree experi-
ments, which yielded essentially the same results (SD < 13%). Adapted from Ref. [15].
394Bruck et al.: Novel treatments in experimental liver damage
PREVENTION OF CON A-INDUCED HEPATITIS BY
SYNTHETIC RGD ANALOGUES
Inhibition ofliver enzymes elevation
BALB/c mice were injected intravenously with 10mg/kg ConA, and treated daily for
5 days prior to ConA inoculation, with either 500 jg/mouse ofone ofthe RGD analogues
SF-6,5 or NS-11, or the RGE analogue SF-6,6 (as a control group). In a previous study,
the RGD analogue SF-6,5 inhibited delayed type hypersensitivity reaction in mice, with
the best results obtained when the mice were injected daily for 5 days prior to the exper-
iment [8]. As expected, the control RGE mimetic, SF-6,6, which has a 12-atom spacing
chain between the two ionic functional groups, and therefore lacks integrin specificity, did
not prevent liverdamage induced by ConA inoculation. In contrast, the RGD mimetic SF-
6,5 effectively decreased the high serum levels ofboth liver enzymes tested (Table 3; Ref.
[15]). When SF-6,5 was administered at a single i.p. dose of 500 jg/mouse 1 hour prior
to ConA injection or orally (at 500 jg/mouse) for 5 days prior to the induction ofhepati-
tis, the increase in serum levels ofliver enzymes was inhibited by only -50 percent (data
not shown). Based on the above data, we concluded that pre-treatment ofthe animals with
the RGD mimetics for 5 days was more effective in the prevention of T-cell-dependent
immune-mediated hepatitis in mice.
Table 3. The effects ofRGD mimetics and peptides on ConA-induced liverinjury in mice.
Inhibitory compound AST ALT
(500 jg/mouse) (IU/l) (IUAl)
NaCl 0.9% 2422 ± 311 4105 ± 473
SF-6,6 (RGE mimetic) 2730 ± 387 4358 ± 680
SF-6,5 (RGD mimetic) 197 ± 43** 167 ± 30**
NS-11 (RGD mimetic) 190 ± 32** 192 ± 35**
GRGDSP (RGD peptide) 2160 ± 410 3360 ± 570
Mean + SEM; n = 6; **p < .01 compared to Con A alone.
Serum levels of liver enzymes were measured 24 hr after Con A (10 mg/kg, i.v.) administration.
Similar results were obtained when liver enzymes were assessed 6 h after the administration ofCon
A (not shown). The RGE and RGD mimetics were administered i.p. daily for 5 days prior to Con A
administration. Adapted from Refs. [15, 16].
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Figure 2. Effect of the synthetic RGD analogue SF-6,5 on serum levels of TNF-a in mice.
Serum levels of TNF-a were measured 2-48 hr after the administration of 10 mg/kg Con A. The
RGD analogue (500 jg/mouse) was administered daily for 5 days prior to and on the day ofCon A
inoculation. Serum levels ofTNF-a were significantly decreased 2 and 6 hr after Con A injection in
the SF-6,5 pretreated mice compared to control mice that received only Con A. Adapted from Ref
[16].
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Table 4. Effects ofthe RGD and RGE mimetics (*SF-6,5 and *SF-6,6) and soluble receptor of
TNF-a on liver histology in Con A-induced liver damage.
Inflammation Necrosis
(0-3) (0-3)
Con A only 2.2 ± 0.4 2.3 ± 0.6
SF-6,6 2.4 ± 0.5 2.5 ± 0.5
SF-6,5 0.6 ± 0.2** 0.4 ± 0.2**
sTNF-R (100 gg/mouse) 0.3 ± 0.1** 0.2 ± 0.1**
*500jig/mouse; Mean ± SD; n = 5; **p < .01 compared to Con A only.
INHIBITION OF TNF-a RELEASE BY SF-6,5
As reported recently, Con A-induced hepatic injury is mediated by cytokines such as
TNF-a, IL-2 and IFN-y[11-13]. The increase in serum levels ofTNF-a in response to Con
A, was inhibited by the RGD mimetic SF-6,5 (Figure 2; Ref. [16]). Thus, the prevention
of Con A-induced liver injury by the RGD mimetic is also associated with inhibition of
TNFa release.
Effects ofthe RGD mimetic SF-6,5 on liver histology
Livers ofcontrol rats, treated with Con A only or with the inactive RGE analogue SF-
6,6, demonstrated areas of intralobular necrosis and inflammatory cell infiltrates around
the central veins and the portal tracts. Inflammatory infiltrates consisted mainly of
mononuclear cells, many of which were positively stained by anti-CD4 by immunohisto-
chemistry. Compatible with previous studies, these results further establish the major role
of the CD4+ T-cell sub population in the etiology and pathogenesis of Con A-induced
hepatitis [11]. As expected, the control RGE mimetic SF-6,6 did not prevent the apparent
liver inflammation. In contrast, in mice treated by the RGD analogue SF-6,5 liver damage
was minimal: no intralobular necrosis or significant inflammatory infiltration could be
demonstrated by light microscopy (Table 4).
Inhibition ofliverdamage by soluble receptor
Hepatic injury in Con A-induced hepatitis is mediated primarily by TNF-a, and this
damage could be prevented by the use ofpolyclonal TNF-oc antiserum [13]. Recombinant
soluble TNF receptors (sTNF-R) have been developed and can be used to neutralize TNF-
a in vivo [5]. Therefore, sTNF-R (p55 recombinant human soluble TNF receptor,
Interpharm, Israel), was administered intravenously, 1 hour prior to Con A injection in
order to prevent liver damage and to confirm the major role ofTNF-y in Con A-induced
hepatitis.
sTNF-R, at a molar ratio of 1:103 or 1:104 to TNF-a (1 or 10 ,ug/mouse respectively,
based on TNF-a serum level measured 2 hr after Con A inoculation), had no effect on the
release of aminotransferases (Table 5). However, sTNF-R, at a molar ratio of 1:105 to
TNF-a (100 jig/mouse), effectively inhibited the Con A-induced elevation of hepatic
enzymes and of TNF-a (Table 5, Figure 3). Thus, in vivo administration of sTNF-R, that
inhibits the increase of serum TNF levels in response to Con A, appears to decrease the
biochemical manifestations ofexperimentally-induced liver damage.
The histopathologic manifestations of liver damage were also prevented by the
administration ofthe sTNFR at a dose of 100 ,ug/mouse (Table 4). Apoptosis ofliver cells
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Table 5. Effect ofsTNF-R on Con A-induced liver injury in mice.
sTNF-R AST ALT
(IU/1) (IU/1)
None 2422 ± 311 4105 ± 520
(1 ,g/mouse) 2670 ± 421 4264 ± 411
(10 gg/mouse) 2111 ± 321 3956 ±508
(100 gg/mouse) 118 ± 27** 22 ± 5**
Mean ± SD; **p < .001I compared to Con A alone; n = 5; Serum levels of liver enzymes were mea-
sured 24 hr after Con A administration (10 mg/kg, i.v.). Adapted from Ref. [16].
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Figure 3. Effect ofsoluble receptor ofTNF on serum levels ofTNF-a in mice. Soluble receptor
ofTNF was administered i.v. at a dose of 100gg/mouse 1 hr prior to Con A administration. Serum
levels ofTNF-a were measured 2-24 hr after the administration of 10 mg/kg Con A, and were sig-
nificantly decreased 2 and 6 hr after Con A injection in the sTNF-R pretreated mice, compared to
control mice that received only ConA. Lower doses ofsTNF-R (1 and 10 rg/mouse) were not effec-
tive in preventing Con A-induced hepatitis. Adapted from Ref. [16].
is an early event in Con A-induced hepatitis, that could be demonstrated histopathologi-
cally as early as 3 hr after the inoculation ofCon A [12]. In liver sections taken from rats
treated with sTNF-R, which were examined 2 and 6 hr after the injection ofCon A, apop-
tosis of liver cells was not detected.
INHIBITION OF HEPATIC FIBROSIS BY THE NON-PEPTIDIC
MIMETIC OF RGD, SF-6,5
A chronic insult induces aprolonged inflammatory process that may lead to the devel-
opment ofliver fibrosis. The process offibrosis appears to result from complex interactions
between extracellular matrix macromolecules, hepatic stellate cells, cytokines and growth
factors. Secreted soluble cytokines, probably link the inflammatory and reparative phase of
liver cirrhosis, by activating hepatic stellate cells (HSC) cells. Upon activation, HSC pro-
liferate and initiate the fibrogenic process by depositing matrix components, such as colla-
gen, glycoproteins (e.g., laminin) andproteoglycans in the space ofDisse, and as the chron-
ic liver insult persists it eventually progresses to nodule formation and cirrhosis [17].
Transforming growth factor (TGF) B contributes to the fibrotic process by modulating
matrix formation by inducing the synthesis of fibronectin, laminin, collagen I, proteogly-
cans and tissue inhibitors ofmetalloproteinases [18, 19]. TGFB also enhances Bi integrin
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expression in a manner that increases cellular adhesion to the matrix proteins [20]. Hence,
the management ofhepatic fibrosis should involve, in addition to suppressing or eliminat-
ing the causative agents ofchronic hepatic inflammation, a specific action on the ECM.
RGD ANALOGUES AND THE INHIBITION OF LIVER FIBROSIS IN RATS
Administration ofthioacetamide and the RGD andRGE analogues
Liver fibrosis was induced by the administration ofthioacetamide (TAA) 0.03 percent
(Sigma Chemical Co., St. Louis, MO) in the drinking water for 12 weeks. The synthesized
SF-6,5 and SF-6,6 were administered i.p. 5 days a week. Rats were treated as follows: One
group received TAA and i.p. injections of 0.9 percent NaCl 5 days a week for 12 weeks
(cirrhotic controls for the RGD-treated groups). Other groups received TAA orally and
either i.p. SF-6,5 (100 jg/day), SF-6,5 (500 jig/day), SF-6,6 (500 ,ug/day) the RGD-con-
taining peptide (GRGDSPK), (Sigma Chemical Co., St. Louis, MO) 500 jg/day for 5
days a week. The control groups consisted ofone that received tap water without TAA for
12 weeks (normal controls) and a group of rats that received only SF-6,5 for 12 weeks to
look for adverse effects.
Liver histopathology
Liver sections were processed for light microscopy including staining the sections
with hematoxylin and eosin, and Masson trichrome. The degree of inflammation and
fibrosis was expressed as the mean of 10 different fields in each slide that had been clas-
sified on a scale of0-3 according to Muller et al. [21].
The administration of the RGD-containing peptide (GRGDSPK) or the RGE ana-
logue SF-6,6 for 12 weeks did not prevent the development of liver cirrhosis (Table 6) in
TAA-treated rats. The livers ofrats that received TAA and a low dose (100 jg/day) ofthe
RGD analogue for 12 weeks showed cirrhotic lesions similar to the group treated with
TAA alone for 12 weeks (Table 6; Ref 22). Thus, a low dose of SF-6,5 was not effective
in preventing liver cirrhosis. In contrast, the livers ofrats that received TAA and a higher
dose (500 jig/day) ofSF-6,5 for 12 weeks showed slight portal and peri-portal inflamma-
tion with mild bridging fibrosis, but no cirrhotic nodules or passive fibrotic septa [22].
Table 6. The effects of nonpeptidic mimetics of RGD and RGE on liver histopathology of
TAA*-treated rats.
Compound used Analogue Inflammation Nodule Fibrotic septa
for treatment (,ug/day) (0-3)*** formation (0-3)***
(12 w) (0-3)***
None 0 0 0 0
TAA 0 1 3 3
TAA+SF-6,5 100 2 2-3 2-3
TAA+SF-6,5 500 1-2 1 1-2
TAA+SF-6,6 500 1 3 3
TAA+GRGDSP 500 1-2 3 3
* 0.03% in drinking water for 12 weeks, unless otherwise indicated.
**For 5 days a week. n = 6 in each group.***No change, 0; slight changes, 1; stronger changes, 2;
and 3; intense changes. Adapted from Ref. [22].
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Quantitative analysis ofliverfibrosis
Hepatic fibrosis was quantitated by computerized imaging morphometry with a com-
puterized video-imaging system (Biological Detection System, Pittsburgh, PA), as previ-
ously described [23]. The mean integrated optical density values of the histologic slides
of the TAA-treated group were significantly higher than those of the TAA plus SF-6,5
(500 ,ug/day) and the control groups (Figure 4A). This quantitative morphometric method
confirmed the results of the histopathologic scoring.
Spleen weights
An indirect measure ofportal hypertension was obtained by measuring the weights of
the rats spleens when treatment was ended. After 12 weeks, the mean spleen weight ofrats
receiving TAA daily was about 80 percent higher than those receiving normal tap water
and injections of 0.9 percent NaCl (Figure 4B). The mean spleen weight of rats that
received SF-6,5 (500 jig/day) in addition to TAA for 12 weeks was only about 30 percent
higher than that of controls.
Side effects ofSF-6,5
A control group consisting of 5 rats received daily only the RGD analogue for 12
weeks. Upon the end oftreatment, no mortality ormajor adverse effects such as infections
or bleeding were observed in the treated rats and blood chemistry and liver histology in
this group appeared normal.
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Figure 4.A) Quantitative determination of the fibrosis in the liver biopsies by computerized imag-
ing morphometry. Integrated optical density depicted as the Mean ± SD; *p < .01 compared with
TAA group. B) Effects ofadministration ofTAA (0.03 percent) and the RGD analogue SF-6,5 (500
jg/day, 5 days/wk) on the spleen weights of rats. Mean ± SD; *p < .01 compared with the group
that received onlyTAA. Note the further decrease in fibrosis and spleen weights when the treatment
with theRGD analogue SF-6,5 was continued foranother2 months afterthe discontinuation ofTAA
Adapted from Ref. [22].
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DISCUSSION
Liver inflammation in Con A-treated mice, characterized by areas of necrosis and
infiltration of liver tissue by mononuclear cells, predominantly CD4+ T-lymphocytes,
could be prevented by synthetic analogues of the RGD sequence and by sTNF-R.
Moreover, the elevation of serumTNF-a, was also inhibited by pretreatment ofmice with
either the RGD mimetic or sTNF-R, suggesting that either neutralization of serum TNF-
a, or inhibition of the interaction between T-lymphocytes and the ECM effectively pre-
vent the cytokine response, and might be one of the mechanisms by which these com-
pounds protect against Con A hepatitis. The inhibition of Con A hepatitis by sTNF-R is
consistent with previous studies that suggested a pivotal role for TNF-a, in the induction
ofCon A-induced liver injury in mice [11-13], and confirm that neutralization ofendoge-
nous TNF-a, by sTNF-R, can prevent liver injury in this model.
The synthetic RGD analogue SF-6,5 was also effective in alleviating hepatic fibrosis
induced by the hepatotoxin TAA. In this rat model, liver cirrhosis results from the inhibi-
tion of respiratory metabolism and enzymatic activity within the nuclei of liver cells by
reactive oxygen species rather than by a direct stimulation of immune cells (although
immune cells are involved in the induction ofcirrhosis by TAA) [24].
During the process of hepatic fibrogenesis, HSC, which in chronically injured liver
are activated by cytokines such as platelet derived growth factor [25], TGF31 [26] and
other factors, acquire amyofibroblast-like phenotype, are the major source ofmatrix com-
ponents in both normal and fibrotic livers [27]. Normal liver subendothelial space is
known to lack a true basement membrane, although the presence of ECM glycoproteins
typical of basement membrane such as collagens, laminin and fibronectin have been
described [28]. Cell-matrix interaction may be important in HSC activation [29]. Recent
studies have shown that the interactions ofepithelial cells with ECM components such as
fibronectin via integrins play an important role in wound healing [30], fibrosis [31] and
hepatic regeneration. One of the earliest detectable changes in the ECM of the insulted
liver is an increase in total FN [32]. In human tenon's capsule fibroblasts adhesion to FN
is an RGD-dependent process [33]. A recent study in HSC in culture have demonstrated
that a5 and PI integrin subunits (fibronectin receptor) are present in both quiescent and
activated HSC, and the increased expression of the a5 and fi subunits during HSC acti-
vation suggests that the fibronectin receptor that binds the RGD sequence may modulate
the differentiation and activation ofHSC in response to changes in the ECM [34]. Hence,
compounds that interfere with the interactions between a5f31 integrin receptors and the
RGD sequence were expected to inhibit fibrogenesis in the liver.
Prevention of RGD-dependent cell-ECM interactions by SF-6,5, may alleviate the
chronic inflammatory response that initiate hepatic fibrogenesis. Inhibition ofthe interac-
tions between inflammatory cells and the ECM by RGD mimetics was proposed, since the
RGD-dependent interaction of resting T-cells and macrophages with ECM components
results in secretion ofTNF-ax and fibroblast growth factor. Moreover, when ECM is phys-
ically damaged, cytokine secretion is enhanced [35]. As shown in mice, the administration
of SF-6,5 effectively inhibited the release ofTNF-a in response to Con A administration.
During inflammation, proteases released by lymphocytes can degrade normal ECM com-
ponents, and in particular FN, to biologically active peptides that are chemoattractants for
fibroblasts [36]. During fibrogenesis, these chemoattracted myofibroblasts complete the
reparative phase by depositing ECM constituents. Therefore, inhibition of myofibroblast
accumulation or activation may alleviate fibrogenesis [34].
It has been reported that RGD-containing peptides can dramatically signal the secre-
tion of proteases such as collagenase and stromelysin from cultured synovial fibroblasts
[37]. Thus, enhancement ofcollagen degradation due to increased production or activity
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of matrix metalloproteinases may also play a role in the inhibition of hepatic fibrosis by
RGD analogues, and this possibility should be tested in future studies.
Thus, nonpeptidic mimetics of cell adhesion motifs can pharmacologically affect
pathological processes involved in hepatic fibrosis. Although the mechanism(s) by which
the RGD analogue induced the antifibrotic effect was not elucidated in our studies, the
processes that may be affected by these mimetics during chronic liver injury include
immune cell migration, cytokine release, activation and adhesion of activated HSC to
ECM or enhancement of collagen degradation due to increased production or activity of
matrix metalloproteinases.
Thus, nonpeptidic analogues of the versatile ECM adhesion epitopes may be effec-
tive in preventing chronic hepatic inflammation and fibrosis, and should be considered
therapeutically to inhibit pathological conditions in the liver. In preliminary studies, no
apparent side effects attributable to SF-6,5 were observed in rats that received only the
RGD mimetic for 12 weeks. However, further efficacy and toxicity studies are indicated
before considering these compounds therapeutically for patients with liver diseases.
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